Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
Amod A. Sarnaik,Omid Hamid,Nikhil I. Khushalani,Karl D. Lewis,Theresa Medina,Harriet M. Kluger,Sajeve Samuel Thomas,Evidio Domingo-Musibay,Anna C. Pavlick,Eric D. Whitman,Salvador Martín-Algarra,Pippa Corrie,Brendan D. Curti,Judit Oláh,Jose Lutzky,Jeffrey S. Weber,James Larkin,Wen Shi,Toshimi Takamura,Madan Jagasia,Harry Qin,Xiao Wu,Cecile Chartier,Friedrich Graf Finckenstein,Maria Fardis,John M. Kirkwood,Jason Chesney +26 more
Reads0
Chats0
TLDR
In this article, the authors discuss the limitations of existing treatment options for patients with advanced melanoma who progress after immune checkpoint inhibitors and targeted therapies, and propose an adaptive cell-based approach.Abstract:
PURPOSEEffective treatment options are limited for patients with advanced (metastatic or unresectable) melanoma who progress after immune checkpoint inhibitors and targeted therapies. Adoptive cell...read more
Citations
More filters
Journal ArticleDOI
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
TL;DR: In this paper , the authors describe the efforts to manipulate the immune system against cancer and discuss different targets and cell types that can be exploited to promote the antitumor immune response.
Journal ArticleDOI
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
Maartje W. Rohaan,Troels Holz Borch,Joost H. van den Berg,Özcan Met,Rob Kessels,Marnix H Geukes Foppen,J. Stoltenborg Granhøj,Bastiaan Nuijen,C.M. Nijenhuis,Inge Jedema,Maaike van Zon,Saskia Scheij,Jos H. Beijnen,Marten Hansen,Carlijn Voermans,Inge Noringriis,Tine Juul Monberg,Rikke B. Holmstroem,L. Wever,M. van Dijk,Lindsay G Grijpink-Ongering,Ludy H.M. Valkenet,A. Torres-Acosta,Matthias Karger,Jessica S.W. Borgers,R M T Ten Ham,Valesca P. Retèl,Wim H. van Harten,Ferry Lalezari,Harm van Tinteren,Astrid A.M. van der Veldt,Geke A. P. Hospers,Marion Stevense-den Boer,Karijn P M Suijkerbuijk,Maureen J.B. Aarts,Djura Piersma,Alfons J.M. van den Eertwegh,Jan Willem B. de Groot,Gerard Vreugdenhil,Ellen Kapiteijn,Marye J Boers-Sonderen,W. Edward Fiets,Franchette W P J van den Berkmortel,Eva Ellebaek,Lisbet Rosenkrantz Hölmich,Alexander C.J. van Akkooi,W. van Houdt,Michel W.J.M. Wouters,Johannes V. van Thienen,Christian U. Blank,A. Meerveld-Eggink,Sebastian Klobuch,Sofie Wilgenhof,Ton N. Schumacher,Marco Donia,Inge Marie Svane,John B. A. G. Haanen +56 more
TL;DR: In this paper , a randomized trial of adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) in treating advanced melanoma was conducted and the primary end point was progression-free survival.
Journal ArticleDOI
Molecular Markers and Targets in Melanoma.
TL;DR: In this article, the authors describe the current knowledge of molecular pathways and discuss current and potential therapeutic targets in melanoma, focusing on their clinical relevance of development, and discuss their clinical significance.
Journal ArticleDOI
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
TL;DR: In this paper , the combination of the multikinase inhibitor lenvatinib and the PD-1 inhibitor pembrolizumab was evaluated in the phase II LEAP-004 study.
Journal ArticleDOI
Novel Immunotherapies for Osteosarcoma
TL;DR: The OS tumor microenvironment is reviewed and the promising immunotherapies available in the management of OS are appraised to help overcome the drawbacks of conventional treatments.
References
More filters
Journal ArticleDOI
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
Elizabeth Eisenhauer,P. Therasse,Jan Bogaerts,Lawrence H. Schwartz,Daniel J. Sargent,Robert Ford,Janet Dancey,S. Arbuck,S. Gwyther,Margaret M. Mooney,Larry Rubinstein,Lalitha K. Shankar,Lori E. Dodd,Robert M. Kaplan,Denis Lacombe,Jaap Verweij +15 more
TL;DR: The revised RECIST includes a new imaging appendix with updated recommendations on the optimal anatomical assessment of lesions, and a section on detection of new lesions, including the interpretation of FDG-PET scan assessment is included.
Journal ArticleDOI
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more
TL;DR: Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma.
Journal ArticleDOI
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov,Serena Nik-Zainal,Serena Nik-Zainal,David C. Wedge,Samuel Aparicio,Sam Behjati,Sam Behjati,Andrew V. Biankin,Graham R. Bignell,Niccolo Bolli,Niccolo Bolli,Åke Borg,Anne Lise Børresen-Dale,Anne Lise Børresen-Dale,Sandrine Boyault,Birgit Burkhardt,Adam Butler,Carlos Caldas,Helen Davies,Christine Desmedt,Roland Eils,Jorunn E. Eyfjord,John A. Foekens,Mel Greaves,Fumie Hosoda,Barbara Hutter,Tomislav Ilicic,Sandrine Imbeaud,Sandrine Imbeaud,Marcin Imielinsk,Natalie Jäger,David T. W. Jones,David T. Jones,Stian Knappskog,Stian Knappskog,Marcel Kool,Sunil R. Lakhani,Carlos López-Otín,Sancha Martin,Nikhil C. Munshi,Nikhil C. Munshi,Hiromi Nakamura,Paul A. Northcott,Marina Pajic,Elli Papaemmanuil,Angelo Paradiso,John V. Pearson,Xose S. Puente,Keiran Raine,Manasa Ramakrishna,Andrea L. Richardson,Andrea L. Richardson,Julia Richter,Philip Rosenstiel,Matthias Schlesner,Ton N. Schumacher,Paul N. Span,Jon W. Teague,Yasushi Totoki,Andrew Tutt,Rafael Valdés-Mas,Marit M. van Buuren,Laura van ’t Veer,Anne Vincent-Salomon,Nicola Waddell,Lucy R. Yates,Icgc PedBrain,Jessica Zucman-Rossi,Jessica Zucman-Rossi,P. Andrew Futreal,Ultan McDermott,Peter Lichter,Matthew Meyerson,Matthew Meyerson,Sean M. Grimmond,Reiner Siebert,Elias Campo,Tatsuhiro Shibata,Stefan M. Pfister,Stefan M. Pfister,Peter J. Campbell,Peter J. Campbell,Peter J. Campbell,Michael R. Stratton,Michael R. Stratton +84 more
TL;DR: It is shown that hypermutation localized to small genomic regions, ‘kataegis’, is found in many cancer types, and this results reveal the diversity of mutational processes underlying the development of cancer.
Journal ArticleDOI
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman,Axel Hauschild,Caroline Robert,John B. A. G. Haanen,Paolo A. Ascierto,James Larkin,Reinhard Dummer,Claus Garbe,Alessandro Testori,Michele Maio,David W. Hogg,Paul Lorigan,Céleste Lebbé,Thomas Jouary,Dirk Schadendorf,Antoni Ribas,Jeffrey A. Sosman,John M. Kirkwood,Brigitte Dréno,K. B. Nolop,Jiang Li,B. Nelson,Jeannie Hou,Richard J. Lee,Keith T. Flaherty,Grant A. McArthur +25 more
TL;DR: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation in a phase 3 randomized clinical trial.
Journal ArticleDOI
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin,Vanna Chiarion-Sileni,Rene Gonzalez,Jean-Jacques Grob,C. Lance Cowey,Christopher D. Lao,Dirk Schadendorf,Reinhard Dummer,Michael Smylie,Piotr Rutkowski,Pier Francesco Ferrucci,A. Hill,John Wagstaff,Matteo S. Carlino,John B A G Haanen,Michele Maio,Ivan Marquez-Rodas,Grant A. McArthur,Paolo A. Ascierto,Georgina V. Long,Margaret K. Callahan,Michael A. Postow,Michael A. Postow,Kenneth F. Grossmann,Mario Sznol,Brigitte Dréno,Lars Bastholt,Arvin Yang,Linda Rollin,Christine Horak,F. Stephen Hodi,Jedd D. Wolchok,Jedd D. Wolchok +32 more
TL;DR: Among previously untreated patients with metastatic melanoma, nivolumab alone or combined with ipilimumab resulted in significantly longer progression-free survival than ipILimumab alone, and in patients with PD-L1-negative tumors, the combination of PD-1 and CTLA-4 blockade was more effective than either agent alone.